AXSM SEC Filings: 8-K, 10-Q, S-3 & 424B

Financials

TYPE

HEADLINE

FILED AT

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 2, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 10, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 4, 2026

10-K

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Feb 23, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 3, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 4, 2025

News

TYPE

HEADLINE

FILED AT

8-K

Axsome Therapeutics Reports Third Quarter 2026 Financial Results and Business Update

Nov 2, 2026

8-K

Axsome Therapeutics Reports Second Quarter 2026 Financial Results and Business Update

Aug 10, 2026

8-K

Axsome Therapeutics Announces FDA Acceptance of New Drug Application for AXS-12 for the Treatment of Cataplexy in Narcolepsy

Jul 15, 2026

8-K

Axsome Therapeutics Adopts New Executive Severance and Change in Control Plan

Jun 9, 2026

8-K

Axsome Therapeutics, Inc. Announces Results of 2026 Annual Meeting of Stockholders

Jun 9, 2026

8-K

Axsome Therapeutics Resolves All SUNOSI Patent Litigation

Jun 3, 2026

Prospectus

TYPE

HEADLINE

FILED AT

424B5

SHELF OFFERING | Shares amount: 3,000,000 | Share price: $75.00 | Offering amount: $225,000,000.00 | Bank: SVB Securities

Jun 28, 2023

424B5

PENDING OFFERING | Bank: SVB Securities

Jun 27, 2023

424B5

ATM | Offering amount: $250,000,000

Aug 19, 2022

424B5

Common Stock-

Mar 1, 2022

424B5

Form 424B5 - Prospectus [Rule 424(b)(5)]

Dec 19, 2019

424B5

Form 424B5 - Prospectus [Rule 424(b)(5)]

Dec 18, 2019

Registrations

TYPE

HEADLINE

FILED AT

S-3ASR

Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers

Nov 3, 2025

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Aug 7, 2025

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Aug 5, 2024

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Jun 23, 2023

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

May 8, 2023

S-3ASR

SHELF | ATM | Offering amount: $250,000,000.00

Dec 2, 2022

Proxies

TYPE

HEADLINE

FILED AT

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 24, 2026

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 24, 2026

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 25, 2025

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 25, 2025

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 26, 2024

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 21, 2023

Ownerships

TYPE

HEADLINE

FILED AT

Jacobson Mark L. (Reporting)

Sep 3, 2026

144

Form 144 - Report of proposed sale of securities

Sep 3, 2026

TABUTEAU HERRIOT (Reporting)

Aug 7, 2026

144

Form 144 - Report of proposed sale of securities

Aug 6, 2026

144

Form 144 - Report of proposed sale of securities

Aug 5, 2026

SCHEDULE 13G/A

BlackRock, Inc. (Filed by)

Jul 27, 2026

Other

TYPE

HEADLINE

FILED AT

Axsome Therapeutics, Inc. AXSM · SEC Filings